Kwon Mi Jeong, Ryu Jai Min, Cho Soo Youn, Nam Seok Jin, Kim Seok Won, Lee Jeeyeon, Lee Soo Jung, Park Ji-Young, Park Ho Yong, Hong Sungjun, Kim Kyunga, Han Jinil, Moon Youngho, Shin Young Kee, Lee Jeong Eon
Vessel-Organ Interaction Research Center, College of Pharmacy, Kyungpook National University, Daegu, South Korea.
Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, South Korea.
Front Oncol. 2021 Feb 23;11:588728. doi: 10.3389/fonc.2021.588728. eCollection 2021.
The prognostic or predictive value of commonly used multigene assays in young patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer is unclear. In this study, we assessed the prognostic value of the GenesWell BCT assay according to age group.
We identified patients with pN0-1, HR+/HER2- breast cancer in a prospective cohort of women who underwent surgery between 2005 and 2017. The GenesWell BCT assay was performed on tissue samples from selected patients. Distant metastasis-free survival (DMFS) and disease-free survival (DFS) were compared between the risk groups assigned by the BCT score.
A total of 712 patients were eligible for analysis. The median follow-up time was 7.47 years. The BCT score was prognostic in patients aged ≤50 years (n = 404) and those aged >50 years (n = 308). In both age groups, the 10-year DMFS and DFS rates for patients classified as high risk by the BCT score were significantly lower than those for patients classified as low risk. A multivariate analysis revealed that the BCT score was an independent prognostic factor for DFS in patients aged ≤50 years (hazard ratio, 1.28; 95% CI, 1.05-1.56; = 0.015), as well as those aged >50 years.
The BCT score could be used to identify low-risk patients who will not benefit from adjuvant chemotherapy to treat HR+/HER2- early breast cancer regardless of age. A further prospective study to assess the prognostic and predictive value of the BCT score is required.
常用多基因检测对激素受体阳性（HR+）、人表皮生长因子受体2阴性（HER2-）的年轻早期乳腺癌患者的预后或预测价值尚不清楚。在本研究中，我们根据年龄组评估了GenesWell BCT检测的预后价值。
我们在2005年至2017年间接受手术的女性前瞻性队列中，确定了pN0-1、HR+/HER2-乳腺癌患者。对选定患者的组织样本进行GenesWell BCT检测。比较BCT评分划分的风险组之间的无远处转移生存期（DMFS）和无病生存期（DFS）。
共有712例患者符合分析条件。中位随访时间为7.47年。BCT评分对年龄≤50岁（n = 404）和年龄>50岁（n = 308）的患者具有预后意义。在两个年龄组中，BCT评分分类为高危患者的10年DMFS和DFS率均显著低于低危患者。多因素分析显示，BCT评分是年龄≤50岁患者DFS的独立预后因素（风险比，1.28；95%CI，1.05-1.56；P = 0.015），对年龄>50岁的患者也是如此。
BCT评分可用于识别无论年龄大小，都不会从辅助化疗中获益的HR+/HER2-早期乳腺癌低风险患者。需要进一步开展前瞻性研究来评估BCT评分的预后和预测价值。
